Oppenheimer Asset Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.6M Sell
17,725
-469
-3% -$264K 0.1% 226
2026
Q1
$10.8M Sell
18,194
-189
-1% -$94.1K 0.12% 191
2025
Q4
$8.96M Sell
18,383
-127
-0.7% -$59.1K 0.11% 212
2025
Q3
$7.76M Buy
18,510
+1,806
+11% +$607K 0.09% 258
2025
Q2
$4.8M Sell
16,704
-412
-2% -$123K 0.06% 354
2025
Q1
$5.28M Sell
17,116
-1,124
-6% -$385K 0.07% 307
2024
Q4
$6.44M Sell
18,240
-6,988
-28% -$2.57M 0.08% 274
2024
Q3
$9.04M Sell
25,228
-624
-2% -$211K 0.11% 212
2024
Q2
$8.24M Buy
25,852
+547
+2% +$145K 0.11% 220
2024
Q1
$5.81M Sell
25,305
-2,228
-8% -$503K 0.09% 260
2023
Q4
$6.05M Sell
27,533
-3,544
-11% -$817K 0.08% 267
2023
Q3
$7.02M Sell
31,077
-1,300
-4% -$299K 0.11% 223
2023
Q2
$7.15M Sell
32,377
-1,060
-3% -$235K 0.11% 224
2023
Q1
$7.49M Sell
33,437
-540
-2% -$133K 0.12% 203
2022
Q4
$9.45M Sell
33,977
-393
-1% -$99.2K 0.15% 173
2022
Q3
$7.2M Sell
34,370
-527
-2% -$118K 0.13% 208
2022
Q2
$8.22M Sell
34,897
-651
-2% -$132K 0.14% 175
2022
Q1
$6.38M Buy
35,548
+2,462
+7% +$469K 0.09% 247
2021
Q4
$7.15M Sell
33,086
-732
-2% -$144K 0.09% 242
2021
Q3
$6.24M Sell
33,818
-777
-2% -$153K 0.09% 266
2021
Q2
$6.21M Buy
+34,595
New +$6.59M 0.09% 264
2020
Q2
Sell
-6
Closed -$1K 1429
2020
Q1
$1K Hold
6
﹤0.01% 1490
2019
Q4
$1K Hold
6
﹤0.01% 1590
2019
Q3
$0 Hold
6
﹤0.01% 1645
2019
Q2
$0 Hold
6
﹤0.01% 1660
2019
Q1
$1K Hold
6
﹤0.01% 1589
2018
Q4
$1K Buy
+6
New +$696 ﹤0.01% 1616
2017
Q4
Sell
-6
Closed -$1K 1476
2017
Q3
$1K Hold
6
﹤0.01% 1658
2017
Q2
$1K Sell
6
-26
-81% -$3.24K ﹤0.01% 1648
2017
Q1
$4K Buy
+32
New +$4.85K ﹤0.01% 1608

Other funds holding UTHR

Oppenheimer Asset Management's UTHR Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its United Therapeutics (UTHR) stake by 2.6% in Q2 2026, selling an estimated $264K and leaving 17,725 shares worth $9.6M. The position accounts for 0.1% of the portfolio, ranked #226.

Oppenheimer Asset Management first reported a position in UTHR in Q1 2017 and has held it in 30 quarters since. The position peaked at $10.8M in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Oppenheimer Asset Management held 17,725 shares of United Therapeutics worth $9.6M as of Q2 2026.
  • Oppenheimer Asset Management sold 469 United Therapeutics shares in Q2 2026, an estimated $264K.
  • United Therapeutics made up 0.1% of Oppenheimer Asset Management's portfolio in Q2 2026, its #226 holding.
  • Oppenheimer Asset Management first reported a position in United Therapeutics in Q1 2017 and has held it in 30 quarters since.
  • Oppenheimer Asset Management's United Therapeutics position peaked at $10.8M in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.